{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:02:18Z","timestamp":1785798138014,"version":"3.56.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRS"],"published-print":{"date-parts":[[2023,1,13]]},"abstract":"<jats:p>BACKGROUND: Antimuscarinics are the backbone of the pharmacological management of overactive bladder. Still, concerns have been raised over the nervous system (NS) adverse drug events (AEs) due to their dissimilarities to muscarinic receptor-subtype affinities. OBJECTIVE: This study aimed to identify the nervous system and gastrointestinal adverse drug events (ADEs) associated with solifenacin use in older adults (\u226565 years). METHODS: A case\/non-case analysis was performed on the reports submitted to the FDA Adverse Event Reporting System (FAERS) between 01\/01\/2004 and 30\/06\/2020. Cases were reports for solifenacin with \u22651 ADEs as preferred terms included in the Medical Dictionary of Regulatory Activities (MedDRA) system organ classes \u2018nervous system\u2019 or \u2018gastrointestinal\u2019 disorders. Non-cases were all other remaining reports for solifenacin. The case\/non-cases was compared between solifenacin and other bladder antimuscarinics. Frequentist approaches, including the proportional reporting ratio (PRR) and reporting odds ratio (ROR), were used to measure disproportionality. The empirical Bayesian Geometric Mean (EBGM) score and information component (IC) value were calculated using a Bayesian approach. A signal was defined as the lower limit of 95% confidence intervals of ROR \u2265\u00a02, PRR \u2265\u00a02, IC &gt;\u00a00, EBGM &gt;\u00a01, for ADEs with \u22654 reports. RESULTS: 107 MedDRA preferred terms (PTs) comprising 970 ADE reports were retrieved for nervous system disorders associated with solifenacin. For gastrointestinal disorders, 129 MedDRA PTs comprising 1817 ADE reports were retrieved. Statistically significant results were found for \u2018altered state of consciousness\u2019: ROR = 9.71 (2.13\u201344.35), PRR = 9.69 (2.12\u201344.2) and IC = 1.29 (0.93\u20131.66). CONCLUSIONS: The disproportionality reporting of \u2018altered state of consciousness\u2019, a previously unidentified ADE, was unexpected. Further monitoring of this ADE is needed to ensure patient safety, as this could be linked to poor balance and falls in older adults.<\/jats:p>","DOI":"10.3233\/jrs-210054","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T14:02:51Z","timestamp":1650981771000},"page":"63-73","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system"],"prefix":"10.1177","volume":"34","author":[{"given":"Connie","family":"Nicholls","sequence":"first","affiliation":[{"name":", University of Bath, , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-yuan","family":"Chyou","sequence":"additional","affiliation":[{"name":", University of Otago, , , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S","family":"Nishtala","sequence":"additional","affiliation":[{"name":"Pharmacy and Pharmacology, Centre for Therapeutic Innovation, University of Bath, , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"5","key":"10.3233\/JRS-210054_ref1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urol"},{"issue":"1","key":"10.3233\/JRS-210054_ref2","first-page":"6","article-title":"Maximising the treatment of overactive bladder in the elderly","volume":"10","author":"Macdiarmid","year":"2008","journal-title":"Rev Urol"},{"issue":"1","key":"10.3233\/JRS-210054_ref3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/TCRM.S1274","article-title":"A review of solifenacin in the treatment of urinary incontinence","volume":"4","author":"Basra","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.3233\/JRS-210054_ref4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","article-title":"Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis","volume":"69","author":"Vouri","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"10.3233\/JRS-210054_ref5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/CIA.S5358","article-title":"The cognitive impact of anticholinergics: A clinical review","author":"Campbell","year":"2009","journal-title":"Clin Interv Aging"},{"issue":"5","key":"10.3233\/JRS-210054_ref6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2009","journal-title":"Br\u00a0J Pharmacol"},{"issue":"1","key":"10.3233\/JRS-210054_ref7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000350029","article-title":"The effect of solifenacin on cognitive function following stroke","volume":"3","author":"Park","year":"2013","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"3","key":"10.3233\/JRS-210054_ref8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neurobiolaging.2007.07.015","article-title":"Blood\u2013brain barrier: Ageing and microvascular disease \u2013 systematic review and meta-analysis","volume":"30","author":"Farrall","year":"2009","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.3233\/JRS-210054_ref9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042098615615472","article-title":"Predicting risk of adverse drug reactions in older adults","volume":"7","author":"Lavan","year":"2015","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"10.3233\/JRS-210054_ref10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40264-020-00928-1","article-title":"A disproportionality analysis of the adverse drug events associated with lurasidone in paediatric patients using the US FDA adverse event reporting system (FAERS)","volume":"43","author":"Rees","year":"2020","journal-title":"Drug Saf"},{"key":"10.3233\/JRS-210054_ref11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yrtph.2018.04.018","article-title":"A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans","volume":"96","author":"Clark","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"issue":"12","key":"10.3233\/JRS-210054_ref12","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/pds.5155","article-title":"Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults","volume":"29","author":"Nishtala","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.3233\/JRS-210054_ref16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidem Drug Saf"},{"issue":"5","key":"10.3233\/JRS-210054_ref17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5414\/CPP43227","article-title":"Effect of age on the pharmacokinetics of solifenacin in men and women","volume":"43","author":"Krauwinkel","year":"2005","journal-title":"Int\u00a0J Clin Pharmacol Ther"},{"issue":"6","key":"10.3233\/JRS-210054_ref18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1517\/14740330903260790","article-title":"Bolodeoku. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10\u00a0mg","volume":"8","author":"Wesnes","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.3233\/JRS-210054_ref19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: The SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.3233\/JRS-210054_ref20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.18926\/AMO\/57368","article-title":"Comparison of two different drugs for overactive bladder, solifenacin and mirabegron: A prospective randomised crossover study","volume":"73","author":"Inoue","year":"2019","journal-title":"Acta Med Okayama"},{"issue":"6","key":"10.3233\/JRS-210054_ref21","doi-asserted-by":"publisher","first-page":"682.e3","DOI":"10.1016\/j.genhosppsych.2013.06.002","article-title":"Solifenacin-induced delirium and hallucinations","volume":"35","author":"\u0160tuhec","year":"2013","journal-title":"Gen Hosp Psych"},{"issue":"5","key":"10.3233\/JRS-210054_ref22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200948050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of solifenacin","volume":"48","author":"Doroshyenko","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.3233\/JRS-210054_ref23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","article-title":"Anticholinergics for overactive bladder therapy: central nervous system effects","volume":"18","author":"Chancellor","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"10.3233\/JRS-210054_ref24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br\u00a0J Clin Pharmacol"},{"issue":"4","key":"10.3233\/JRS-210054_ref25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.bbamem.2008.10.022","article-title":"The blood-brain barrier in brain homeostasis and neurological diseases","volume":"1788","author":"Weiss","year":"2009","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"4","key":"10.3233\/JRS-210054_ref26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00345-013-1179-z","article-title":"Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study","volume":"32","author":"Burger","year":"2014","journal-title":"World\u00a0J Urol"},{"issue":"3","key":"10.3233\/JRS-210054_ref27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000455257","article-title":"Solifenacin in the elderly: Results of an observational study measuring efficacy, tolerability and cognitive effects","volume":"98","author":"Hampel","year":"2017","journal-title":"Urol Int"},{"issue":"2","key":"10.3233\/JRS-210054_ref28","doi-asserted-by":"publisher","first-page":"e16718-e","DOI":"10.1371\/journal.pone.0016718","article-title":"Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach","volume":"6","author":"Kessler","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.3233\/JRS-210054_ref29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","article-title":"An experimental investigation of masking in the US FDA adverse event reporting system database","volume":"33","author":"Wang","year":"2010","journal-title":"Drug Saf"},{"issue":"4","key":"10.3233\/JRS-210054_ref30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"E\u00a0J Clin Pharmacol"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JRS-210054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:33Z","timestamp":1777509933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JRS-210054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":27,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jrs-210054","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}